Diffuse large B cell lymphoma laboratory tests: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Laboratory Tests== | ==Laboratory Tests== | ||
Laboratory studies include<ref>{{cite web | title = Non-Hodgkin's Lymphomas (NCCN.org) | url = http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf }}</ref> | |||
* Complete Blood Picture | * Complete Blood Picture | ||
* Serum lactate dehydrogenase (LDH) | * Serum lactate dehydrogenase (LDH) | ||
Revision as of 14:48, 24 August 2015
|
Diffuse large B cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diffuse large B cell lymphoma laboratory tests On the Web |
|
American Roentgen Ray Society Images of Diffuse large B cell lymphoma laboratory tests |
|
Directions to Hospitals Treating Diffuse large B cell lymphoma |
|
Risk calculators and risk factors for Diffuse large B cell lymphoma laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Tests
Laboratory studies include[1]
- Complete Blood Picture
- Serum lactate dehydrogenase (LDH)
- Comprehensive metabolic panel
- CT chest/abdominal/pelvic with oral and intravenous contrast (unless co-existent renal insufficiency)
- MUGA scan or echocardiograms are recommended when anthracyclines and anthracenedione containing regimens are used
- Bone marrow biopsy with or without aspirate is essential in all cases where treatment is considered; however, there are circumstances where it may be deferred
- Hepatitis B testing prior to initiation of treatment in all patients who will receive anti CD20 monoclonal antibody-based regimens and anyone with a risk factor
- Hepatitis C testing is needed in high-risk patients